Coherus has entered into privately negotiated transactions with certain holders of its 1.500% Convertible Senior Subordinated Notes due 2026, ...

Remaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture – REDWOOD CITY, Calif., ...

April 8 (Reuters) - President Donald Trump on Tuesday said the U.S. will soon announce a "major" tariff on pharmaceutical imports. Speaking to an event at the National Republican Congressional ...

SOUTH SAN FRANCISCO, Calif., April 4, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals ...

RANCHO CUCAMONGA, CA / ACCESS Newswire / April 3, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication ...

President Trump wants to bring pharmaceutical manufacturing back to the United States. Experts warn that tariffs could result in shortages and higher prices for generic drugs. By Rebecca Robbins ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, let’s get straight into all the news today. In his ...

Max, formerly known as HBO Max, officially has a new logo on Sunday night, March 30. The new logo for Warner Bros. Discovery's steaming platform was unveiled on Sunday evening. The new logo gives ...

It offers a sustainable - and affordable – alternative to synthesizing important peptide-based pharmaceuticals, thanks to a plant-based production system known as biopharming. The project ...

Apr. 1, 2025 — A team has developed a new way to quickly find personalized treatments for young cancer patients, by growing their tumors in chicken eggs and ... Could an Arthritis Drug Unlock ...

TEL AVIV, Israel, April 2, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on ...

Blog posts represent the views of CFR fellows and staff and not those of CFR, which takes no institutional positions. Most of the major U.S. pharmaceutical companies (AbbVie, Amgen, Bristol Myers ...